Skip to content

Diabetes Discharge Transitional CGM Study (DDT-CGM)

Daibetes Discharge Transitional CGM Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04729985
Acronym
DDT-CGM
Enrollment
120
Registered
2021-01-29
Start date
2021-06-01
Completion date
2024-12-01
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

hospital discharge, Continuous Glucose Monitoring, Type 2 diabetes, rehospitalization

Brief summary

Intervention group will receive brief diabetic education, CGM education and use and have a CGM placed before discharge. They will also sign up for Cloud access of their CGM data. A medical assistant will review their CGM data daily to make sure they are using the CGM adequately. The principal investigator will review the CGM data and call the patient for a brief phone evaluation of their glucoses and their transition from the hospital to outpatient care. The will be called 4 times between discharge and day 15 by the principal investigator. Standard treatment group will receive a blinded CGM to be reviewed 30 days after discharge. Reduction in hospitalizations and ER visits within the first 30 days is the primary outcome. Time in range, hypoglycemia, hyperglycemia and patient satisfaction will also be evaluated 30 days after discharge.

Detailed description

Patients admitted to a community hospital with diabetes will be evaluated for being high risk for rehospitalization. High risk patients will be identified and those that are found to be high risk will be evaluated for entrance to the study and consented. Those that consent will be randomized to two arms, an intervention arm and a standard care arm with CGM monitoring. Intervention will include a brief 15 minute diabetic education session and a 15 minute brief education on how to use the Freestyle Libre CGM. A sensor will be placed and initiated before discharge. They will also sign up for a Freestyle Libre View account and grant access to the intervention team. The will receive a handout of reasons to call the principal investigator during the first 15 days and will be told to access the PI through the hospital operator. The PI will call the patient on day 3-4, day 5-6, day 9-10 and day 14-15 after reviewing their CGM data. The PI will review their glucoses and also any concerns from their hospitalization. The team can then help bridge any treatment or care gaps with the patients PCP or care team. The CGM data will be recorded for the first 14 days and data will be sent to the PCP. The standard treatment arm will get 15 minutes of education on how to use the Libre Pro blinded CGM sensor and the sensor will be placed before discharge. The sensor will be sent back the the team and downloaded. After 30 days the data will be sent to the patients PCP. Outcomes will be measured for 30 days from discharge. Patient satisfaction will be measured by a phone interview in both groups once after 31-40 days from discharge

Interventions

DEVICECGM device with diabetic education, CGM education and a follow up protocol.

Blind CGM placed and recorded for 14 days after discharge and data downloaded

Sponsors

Abbott
CollaboratorINDUSTRY
Intermountain Health Care, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Data evaluation group will be blinded as to which arm the data comes from

Intervention model description

Prospective Randomized Trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Type 2 diabetes plus one additional criteria during hospitalization: A1C greater than or equal to 9, New diagnosis of diabetes Type 2 and A1C greater than or equal to 8, On insulin, On sulfonylurea, Deemed to by high risk by hospitalist staff for post-hospitalization complications, Acute Heart Failure, Acute Coronary Syndrome (ACS), Stroke, or a TIA. \-

Exclusion criteria

Type 1 Diabetes, or Not high risk (as above), or Already using a CGM, or Unable to understand or use a CGM, or Unable or unwilling to use a CGM, or Participating in another clinical trial within 30 days. \-

Design outcomes

Primary

MeasureTime frameDescription
Emergency room visit and rehospitalizationWithin 30 days after discharge from the hospitalTotal Emergency room visits and total rehospitalizations

Secondary

MeasureTime frameDescription
RehospitalizationsWithin 30 days after discharge from the hospitalTotal Rehospitalizations
Time in rangeFrom discharge to day 14percent of time glucose is in range from 70-180 mg/dl as measured by CGM
time in hypoglycemiafrom discharge through day 14amount of time below 70 mg/dl as measured by CGM
Emergency room visitsWithin 30 days after discharge from the hospitalTotal Emergency room visits
time in hyperglycemiaFrom discharge through day 14glucose from 181-250 mg/dl as measured by CGM
time in severe hyperglycemiafrom discharge through day 14glucose greater than 251 mg/dl as measured by CGM
Patient satisfactionsurvey will be done between 31 and 40 days after hospital dischargePatient telephone questionnaire about patient satisfaction during the transition phase
Severe hypoglycemiafrom discharge to day 30hypoglycemia requiring the assistance from another person

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026